FDA clears Sanofi's Sarclisa Escena via on-body injector for myeloma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
July 10, 2026 8:35 AM EDTSanofis subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sarclisa Escena administered via the CirCLIQ® on-body injector (OBI) offers a treatment experience designed with patients and HCPs in mindThe first anticancer treatment to be administered through an OBI, and the first MM treatment available by both SC OBI and manual SC administration in the USEfficacy of Sarclisa now available in SC formulation with innovative OBI across approved combinations and lines of therapy... More
